Accumetrics platelet response test could guide therapy after CE marking
This article was originally published in Clinica
Executive Summary
Accumetrics has CE marked its VerifyNow P2Y12 test for the identification of poor responders to antiplatelet therapy. Patients who do not respond well to antiplatelet drugs, which inhibit the P2Y12 receptor and therefore blood clotting, are at greater risk for future cardiovascular events.